


## VALUATION MULTIPLES

**Forward EV / EBITDA Multiples (monthly to 28/02/2021)** Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have decreased over the period. At the end of February, the sector traded on a forward EV / EBITDA multiple of 9.1x, compared to the ASX200 on 10.5x.



**Average Values and Trading Multiples (values as at 29/03/2021)** Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2021	EV/EBIT FY2021	Price / Earnings FY2021
Aged Care	786	6.9x	11.3x	28.4x
Animal Health	148	9.6x	16.1x	15.8x
Biotech	126,910	26.8x	30.9x	39.5x
Hospitals & Clinics	47,223	9.8x	14.9x	20.0x
<b>Healthcare</b>	<b>178,285</b>	<b>10.5x</b>	<b>15.2x</b>	<b>20.9x</b>

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2021. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: October 2020.

## MERGER & ACQUISITION NEWS...

---



### REVENIO

Value: AUD 18.5m

**Capstone Health** provides specialist medical and emergency services to the energy, mining, and infrastructure industries, and has been acquired by **Fullerton Health Australia's** remote services division **Baseline Group**. The acquisition of Capstone Health sees Fullerton Health Australia continue to build on its national growth plans.

---

## UNDER THE MICROSCOPE...

---

- **Medibank**, an Australia-based health insurer, is thought to be eyeing **Healthe Care's** acute care hospitals.
- **Australian Unity Healthcare Property Trust's** responsible entity, **Australian Unity Funds Management Limited**, advised in a letter to investors on 26 March that it has rejected **NorthWest Healthcare Properties Real Estate Investment Trust's** revised offer of AUD 2.35 per unit.
- **CSL**, an Australia-based healthcare company, could take advantage of its strong market performance to pursue an acquisition.
- **Medibank** has entered into a joint venture with 42 specialist doctors to develop a new short-stay, no-gap surgical facility on a site in Kew, Melbourne.
- A positive Phase III result reading for **Neuren Pharma** could provoke some sort of corporate action from larger players towards the Australian developer of therapies for neurodegenerative disorders.
- **Cornerstone Health**, an Australian medical centres owner, is seeking a cornerstone investor.
- **QBiotics**, an Australia-based pharmaceutical company, has raised AUD 50m (USD 39m) in funding from **TDM Growth Partners**.
- **Pacific Radiology**, a privately held New Zealand-based radiology and imaging services provider, could come up for sale this year.
- Australia's **Plenary Health** and Japan's **Sojitz Corp.** have reached financial close on the AUD 1.5bn Footscray Hospital public private partnership.
- **Doctors on Demand**, an Australia-based telehealth platform, plans to list within the next year.
- **BWXT Medical**, an Ottawa, Ontario-based subsidiary of **BWX Technologies** and **Global Medical Solutions**, have formed a joint venture in nuclear medicine manufacturing and distribution in the APAC region.
- **Visioneering Technologies**, the ASX-listed eyesight medical device company, will seek inorganic opportunities including partnerships or acquisitions and is "always on the lookout" for strategic fits.
- **Island Pharmaceuticals**, an Australia-based antiviral drug developer, is seeking to raise AUD 7.5m through an initial public offering (IPO) on the Australian Securities Exchange (ASX).
- **Healthia**, the Australia-based health services business, is eyeing further acquisitions.
- **Medtech Global**, the New Zealand-headquartered provider of medical practice management software, could seek acquisitions to accelerate growth under new majority owner **Advent Partners**, a Melbourne-based private equity investor.
- Australian pharma manufacturer and distributor **Probiotec** is assessing a range of acquisition opportunities.
- **CleanSpace Holdings**, an Australia-based manufacturer of respirator masks for healthcare workers as well as for use in other industries, is exploring acquisition opportunities.
- The group strategy of **Ramsay Healthcare**, an Australia-based healthcare provider, includes acquisitions.
- **Regis Healthcare**, an Australia-based aged-care business, is well-placed to take advantage of acquisition opportunities.

## CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	(07) 3218 9122	<a href="mailto:sdoyle@interfinancial.com.au">sdoyle@interfinancial.com.au</a>
Paul Keehan	Non-Executive Director	(07) 3218 9100	<a href="mailto:pkeehan@interfinancial.com.au">pkeehan@interfinancial.com.au</a>
Ted Marchant	Non-Executive Director	(07) 3218 9100	<a href="mailto:tmarchant@interfinancial.com.au">tmarchant@interfinancial.com.au</a>
Mark Steinhardt	Head of M&A	(07) 3218 9105	<a href="mailto:msteinhardt@interfinancial.com.au">msteinhardt@interfinancial.com.au</a>
Brad Shaw	Director – M&A	(07) 3218 9100	<a href="mailto:bshaw@interfinancial.com.au">bshaw@interfinancial.com.au</a>
Brent Wall	Director – M&A	(07) 3218 9102	<a href="mailto:bwall@interfinancial.com.au">bwall@interfinancial.com.au</a>
David Hassum	Director	(07) 3218 9108	<a href="mailto:dhassum@interfinancial.com.au">dhassum@interfinancial.com.au</a>
Andrew Wheeler	Director	(07) 3218 9107	<a href="mailto:awheeler@interfinancial.com.au">awheeler@interfinancial.com.au</a>
Michael Kakanis	Associate Director	(07) 3218 9106	<a href="mailto:mkakanis@interfinancial.com.au">mkakanis@interfinancial.com.au</a>
Lachlan O'Rourke	Analyst	(07) 3218 9104	<a href="mailto:lorourke@interfinancial.com.au">lorourke@interfinancial.com.au</a>
Justin Ridgway-Cross	Research Analyst	(07) 3218 9100	<a href="mailto:jridgwaycross@interfinancial.com.au">jridgwaycross@interfinancial.com.au</a>

## DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

**Important Disclaimer** – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

**Disclosure.** InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

*InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.*

InterFinancial  
Corporate Finance Limited  
ABN: 49 136 962 966  
AFSL: 341675  
Level 2, 201 Charlotte Street  
GPO Box 975  
Brisbane Queensland 4001  
(07) 3218 9100  
admin@interfinancial.com.au  
www.interfinancial.com.au

